Week In Review: Innovent Out-Licenses Ex-China Rights For PD-1 To Lilly In $1 Billion Deal
August 22, 2020 at 14:53 PM EDT
Suzhou Innovent Bio expanded its 2015 alliance with Eli Lilly for Tyvyt®, Innovent's anti-PD-1 immunotherapy. In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets.
